Driver or passenger effects of augmented c-Myc and Cdc20 in gliomagenesis

Ping Ji, Xinhui Zhou, Qun Liu, Gregory N. Fuller, Lynette M. Phillips, Wei Zhang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: Cdc20 and c-Myc are commonly overexpressed in a broad spectrum of cancers, including glioblastoma (GBM). Despite this clear association, whether c-Myc and Cdc20 overexpression is a driver or passenger event in gliomagenesis remains unclear. Results: Both c-Myc and Cdc20 induced the proliferation of primary glial progenitor cells. c-Myc also promoted the formation of soft agar anchorage-independent colonies. In the RCAS/Ntv-a glia-specific transgenic mouse model, c-Myc increased the GBM incidence from 19.1% to 47.4% by 12 weeks of age when combined with kRas and Akt3 in Ntv-a INK4a-ARF (also known as CDKN2A)-null mice. In contrast, Cdc20 decreased the GBM incidence from 19.1% to 9.1%. Moreover, cell differentiation was modulated by c-Myc in kRas/Akt3-induced GBM on the basis of Nestin/GFAP expression (glial progenitor cell differentiation), while Cdc20 had no effect on primary glial progenitor cell differentiation. Materials and Methods: We used glial progenitor cells from Ntv-a newborn mice to evaluate the role of c-Myc and Cdc20 in the proliferation and transformation of GBM in vitro and in vivo. We further determined whether c-Myc and Cdc20 have a driver or passenger role in GBM development using kRas/Akt3 signals in a RCAS/ Ntv-a mouse model. Conclusions: These results suggest that the driver or passenger of oncogene signaling is dependent on cellular status. c-Myc is a driver when combined with kRas/Akt3 oncogenic signals in gliomagenesis, whereas Cdc20 overexpression is a passenger. Inhibition of cell differentiation of c-Myc may be a target for anti-glioma therapy.

Original languageEnglish (US)
Pages (from-to)23521-23529
Number of pages9
JournalOncotarget
Volume7
Issue number17
DOIs
StatePublished - Apr 26 2016

Fingerprint

Glioblastoma
Neuroglia
Cell Differentiation
Stem Cells
Nestin
Incidence
Oncogenes
Glioma
Transgenic Mice
Agar
Neoplasms

Keywords

  • Cdc20
  • Glial progenitor cell differentiation
  • Glioblastoma
  • Myc
  • RCAS/Ntv-a glia-specific mouse model

ASJC Scopus subject areas

  • Oncology

Cite this

Ji, P., Zhou, X., Liu, Q., Fuller, G. N., Phillips, L. M., & Zhang, W. (2016). Driver or passenger effects of augmented c-Myc and Cdc20 in gliomagenesis. Oncotarget, 7(17), 23521-23529. https://doi.org/10.18632/oncotarget.8080

Driver or passenger effects of augmented c-Myc and Cdc20 in gliomagenesis. / Ji, Ping; Zhou, Xinhui; Liu, Qun; Fuller, Gregory N.; Phillips, Lynette M.; Zhang, Wei.

In: Oncotarget, Vol. 7, No. 17, 26.04.2016, p. 23521-23529.

Research output: Contribution to journalArticle

Ji, P, Zhou, X, Liu, Q, Fuller, GN, Phillips, LM & Zhang, W 2016, 'Driver or passenger effects of augmented c-Myc and Cdc20 in gliomagenesis', Oncotarget, vol. 7, no. 17, pp. 23521-23529. https://doi.org/10.18632/oncotarget.8080
Ji P, Zhou X, Liu Q, Fuller GN, Phillips LM, Zhang W. Driver or passenger effects of augmented c-Myc and Cdc20 in gliomagenesis. Oncotarget. 2016 Apr 26;7(17):23521-23529. https://doi.org/10.18632/oncotarget.8080
Ji, Ping ; Zhou, Xinhui ; Liu, Qun ; Fuller, Gregory N. ; Phillips, Lynette M. ; Zhang, Wei. / Driver or passenger effects of augmented c-Myc and Cdc20 in gliomagenesis. In: Oncotarget. 2016 ; Vol. 7, No. 17. pp. 23521-23529.
@article{f138a170361a42d68f9c03185fe3ff63,
title = "Driver or passenger effects of augmented c-Myc and Cdc20 in gliomagenesis",
abstract = "Purpose: Cdc20 and c-Myc are commonly overexpressed in a broad spectrum of cancers, including glioblastoma (GBM). Despite this clear association, whether c-Myc and Cdc20 overexpression is a driver or passenger event in gliomagenesis remains unclear. Results: Both c-Myc and Cdc20 induced the proliferation of primary glial progenitor cells. c-Myc also promoted the formation of soft agar anchorage-independent colonies. In the RCAS/Ntv-a glia-specific transgenic mouse model, c-Myc increased the GBM incidence from 19.1{\%} to 47.4{\%} by 12 weeks of age when combined with kRas and Akt3 in Ntv-a INK4a-ARF (also known as CDKN2A)-null mice. In contrast, Cdc20 decreased the GBM incidence from 19.1{\%} to 9.1{\%}. Moreover, cell differentiation was modulated by c-Myc in kRas/Akt3-induced GBM on the basis of Nestin/GFAP expression (glial progenitor cell differentiation), while Cdc20 had no effect on primary glial progenitor cell differentiation. Materials and Methods: We used glial progenitor cells from Ntv-a newborn mice to evaluate the role of c-Myc and Cdc20 in the proliferation and transformation of GBM in vitro and in vivo. We further determined whether c-Myc and Cdc20 have a driver or passenger role in GBM development using kRas/Akt3 signals in a RCAS/ Ntv-a mouse model. Conclusions: These results suggest that the driver or passenger of oncogene signaling is dependent on cellular status. c-Myc is a driver when combined with kRas/Akt3 oncogenic signals in gliomagenesis, whereas Cdc20 overexpression is a passenger. Inhibition of cell differentiation of c-Myc may be a target for anti-glioma therapy.",
keywords = "Cdc20, Glial progenitor cell differentiation, Glioblastoma, Myc, RCAS/Ntv-a glia-specific mouse model",
author = "Ping Ji and Xinhui Zhou and Qun Liu and Fuller, {Gregory N.} and Phillips, {Lynette M.} and Wei Zhang",
year = "2016",
month = "4",
day = "26",
doi = "10.18632/oncotarget.8080",
language = "English (US)",
volume = "7",
pages = "23521--23529",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "17",

}

TY - JOUR

T1 - Driver or passenger effects of augmented c-Myc and Cdc20 in gliomagenesis

AU - Ji, Ping

AU - Zhou, Xinhui

AU - Liu, Qun

AU - Fuller, Gregory N.

AU - Phillips, Lynette M.

AU - Zhang, Wei

PY - 2016/4/26

Y1 - 2016/4/26

N2 - Purpose: Cdc20 and c-Myc are commonly overexpressed in a broad spectrum of cancers, including glioblastoma (GBM). Despite this clear association, whether c-Myc and Cdc20 overexpression is a driver or passenger event in gliomagenesis remains unclear. Results: Both c-Myc and Cdc20 induced the proliferation of primary glial progenitor cells. c-Myc also promoted the formation of soft agar anchorage-independent colonies. In the RCAS/Ntv-a glia-specific transgenic mouse model, c-Myc increased the GBM incidence from 19.1% to 47.4% by 12 weeks of age when combined with kRas and Akt3 in Ntv-a INK4a-ARF (also known as CDKN2A)-null mice. In contrast, Cdc20 decreased the GBM incidence from 19.1% to 9.1%. Moreover, cell differentiation was modulated by c-Myc in kRas/Akt3-induced GBM on the basis of Nestin/GFAP expression (glial progenitor cell differentiation), while Cdc20 had no effect on primary glial progenitor cell differentiation. Materials and Methods: We used glial progenitor cells from Ntv-a newborn mice to evaluate the role of c-Myc and Cdc20 in the proliferation and transformation of GBM in vitro and in vivo. We further determined whether c-Myc and Cdc20 have a driver or passenger role in GBM development using kRas/Akt3 signals in a RCAS/ Ntv-a mouse model. Conclusions: These results suggest that the driver or passenger of oncogene signaling is dependent on cellular status. c-Myc is a driver when combined with kRas/Akt3 oncogenic signals in gliomagenesis, whereas Cdc20 overexpression is a passenger. Inhibition of cell differentiation of c-Myc may be a target for anti-glioma therapy.

AB - Purpose: Cdc20 and c-Myc are commonly overexpressed in a broad spectrum of cancers, including glioblastoma (GBM). Despite this clear association, whether c-Myc and Cdc20 overexpression is a driver or passenger event in gliomagenesis remains unclear. Results: Both c-Myc and Cdc20 induced the proliferation of primary glial progenitor cells. c-Myc also promoted the formation of soft agar anchorage-independent colonies. In the RCAS/Ntv-a glia-specific transgenic mouse model, c-Myc increased the GBM incidence from 19.1% to 47.4% by 12 weeks of age when combined with kRas and Akt3 in Ntv-a INK4a-ARF (also known as CDKN2A)-null mice. In contrast, Cdc20 decreased the GBM incidence from 19.1% to 9.1%. Moreover, cell differentiation was modulated by c-Myc in kRas/Akt3-induced GBM on the basis of Nestin/GFAP expression (glial progenitor cell differentiation), while Cdc20 had no effect on primary glial progenitor cell differentiation. Materials and Methods: We used glial progenitor cells from Ntv-a newborn mice to evaluate the role of c-Myc and Cdc20 in the proliferation and transformation of GBM in vitro and in vivo. We further determined whether c-Myc and Cdc20 have a driver or passenger role in GBM development using kRas/Akt3 signals in a RCAS/ Ntv-a mouse model. Conclusions: These results suggest that the driver or passenger of oncogene signaling is dependent on cellular status. c-Myc is a driver when combined with kRas/Akt3 oncogenic signals in gliomagenesis, whereas Cdc20 overexpression is a passenger. Inhibition of cell differentiation of c-Myc may be a target for anti-glioma therapy.

KW - Cdc20

KW - Glial progenitor cell differentiation

KW - Glioblastoma

KW - Myc

KW - RCAS/Ntv-a glia-specific mouse model

UR - http://www.scopus.com/inward/record.url?scp=84966593343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966593343&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8080

DO - 10.18632/oncotarget.8080

M3 - Article

VL - 7

SP - 23521

EP - 23529

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 17

ER -